EcoDrugPlus

Fibroblast Activation Protein Alpha

Ensembl ID : ENSCPOG00000011995
Gene Symbol: FAP
2 Cross references
127 Possible Orthologues:

Fibroblast Growth Factor 2

Ensembl ID : ENSCPOG00000005386
Gene Symbol: FGF2
1 Cross references
117 Possible Orthologues:

Fibroblast Growth Factor Receptor 1

Ensembl ID : ENSCPOG00000006553
Gene Symbol: FGFR1
4 Cross references
293 Possible Orthologues:

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSCPOG00000008833
Gene Symbol: FGFR2
2 Cross references
218 Possible Orthologues:

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSCPOG00000025595
Gene Symbol: FGFR3
2 Cross references
196 Possible Orthologues:

Fibroblast Growth Factor Receptor 4

Ensembl ID : ENSCPOG00000022113
Gene Symbol: FGFR4
4 Cross references
123 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSCPOG00000013357
Gene Symbol: FLT1
4 Cross references
199 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 3

Ensembl ID : ENSCPOG00000007285
Gene Symbol: FLT3
4 Cross references
134 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSCPOG00000008026
Gene Symbol: FLT4
4 Cross references
198 Possible Orthologues:

Folate Hydrolase 1

Ensembl ID : ENSCPOG00000003797
Gene Symbol: FOLH1
2 Cross references
211 Possible Orthologues:

Folate Receptor Alpha

Ensembl ID : ENSCPOG00000012539
Gene Symbol: FOLR1
2 Cross references
204 Possible Orthologues:

Follicle Stimulating Hormone Receptor

Ensembl ID : ENSCPOG00000011752
Gene Symbol: FSHR
2 Cross references
200 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).